Ind-Swift Laboratories share news, announcements and annual reports
NSE: INDSWFTLABBSE: 532305Pharmaceuticals & BiotechnologySmall Cap
Ind-Swift Laboratories Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jul 1997 on NSE, Mar 2000 on BSE
Last close ₹368.20down ₹41.60 (10.15%)BSE ₹367.40
Share price at the NSE close on 30 Oct 2026. Previous close ₹409.80.
30 Oct: open ₹417.90, high ₹426.60, low ₹352.35
52-week range of traded prices to 30 Oct 2026
₹87.15Low, 31 Dec 2025₹426.60High, 30 Oct 2026
- Under NSE's long-term additional surveillance, stage I, on the list for 30 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹3,202 Cr1,404th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 38.32
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹12 crore of one-off items, the largest of them in the quarter to Dec 2025.
- 33.57
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.17
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 6.0%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹12 crore of one-off items, the largest of them in the quarter to Dec 2025.
- 6.9%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 4.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.01
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 36,07,65931.1% delivered
Ind-Swift Laboratories share news and announcements
911 announcements, routine notices left out, newest first. Page 19 of 19.
Apr 2007
24 Apr · Board meeting
Meeting on 30 Apr 2007: “Unaudited Financial Results for the Qtr ended March 31, 2007”
Mar 2007
29 Mar · Allotment of shares
Ind-Swift Laboratories Ltd. has informed the Exchange that: "The Board of Directors of the Company have in its meeting held on today i.e. 28th March, 2007 allotted 3,35,000 equity shares upon conversion of 3,35,000 Zero Coupon Convertible warrants belonging to Promoters group Company M/s. Ind-Swift Limited at a price of Rs.70/- per share".23 Mar · Board meeting
To consider and approve interalia, among other items, part allotment of shares upon conversion of Zero Coupon Convertible warrants into equity shares of the holders of warrants.23 Mar · Meeting
Ind-Swift Laboratories Ltd. has submitted the Exchange a copy of proceedings of the Minutes of the Extra-Ordinary General Meeting of the Company held on February 23, 2007. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements). For more details click here.12 Mar · Board meeting
Ind-Swift Laboratories Ltd. has informed the Exchange that "the Board Meeting of the Company which was earlier scheduled to be held on March 08, 2007, eventually held on March 10, 2007, has allotted 28,00,000 Zero Coupon Convertible warrants on preferential basis to Promoters group Companies".12 Mar · Board meeting
Ind-Swift Laboratories Ltd. has informed the Exchange that "the Board of Directors of the Company have in its meeting held on today i.e. 10th March, 2007, allotted 28,00,000, Zero Coupon Optionally Convertible Warrants into Equity Shares to Promoters Group Companies at a price of Rs.70/- per warrant".5 Mar · Board meeting
For allotment of Convertible warrants on preferential basis to Promoters Group Companies.
Feb 2007
26 Feb · Meeting
Ind-Swift Laboratories Ltd. has informed the Exchange that "The shareholders of the Company, in its Extra Ordinary General Meeting held on 23.02.2007 have approved the issue of 28,00,000 Zero Coupon Optionally Convertible Warrants into Equity Shares to Promoters Group Companies at a price of Rs. 70/- per warrant."8 Feb · Business
Ind-Swift Laboratories Ltd. has informed the Exchange regarding a press release, titled "Ind-Swift Laboratories Limited undergoes successful USFDA audit". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jan 2007
25 Jan · Meeting
Ind-Swift Laboratories Ltd. has informed the Exchange on January 24, 2007 that "the Board has in its meeting held today apporved inter-alia the following; (1) Issue of 28,00,000 Zero Coupon optionally Convertible Warrants into Equity Shares to Promoters Group Companies. (2) To hold the Extra Ordinary General Meeting of the Company on 23.02.2007".17 Jan · Board meeting
To consider inter-alia, Quarterly Unaudited Financial Results (Provisional) for the quarter ended 31st December, 2006.